Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$5.2M
Filings
120
Firms Hired
5
Active Period
2011–2018
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Protecting Access to Medicare Act of 2014
2018 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Client expense: — · Firm income: —
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Client expense: — · Firm income: —
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Client expense: — · Firm income: —
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests. FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Client expense: — · Firm income: —
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · second_quarter · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2018 · second_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2018 · first_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare treatment of outpatient reimbursement for laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Advancing Access to Precision Medicine Act
2018 · first_quarter · Firm: MYRIAD GENETIC LABORATORIES INC
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests Billing rules for laboratory tests; date of service rule/14 day rule National Coverage Decision on next generation sequencing tests HR 5062 - Advancing Access to Precision Medicine Act
Client expense: $200,000 · Firm income: —
Matched citations: HR 5062
Protecting Access to Medicare Act of 2014
2018 · first_quarter · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2017 · fourth_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2017 · fourth_quarter · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2017 · third_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2017 · third_quarter · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2017 · second_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2017 · second_quarter · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2017 · first_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2017 · first_quarter · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Client expense: — · Firm income: $30,000
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2016 · fourth_quarter · Firm: TODD STRATEGY GROUP
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payment for clinical laboratory tests. FDA regulation of laboratory developed tests. Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4302
Protecting Access to Medicare Act of 2014
2016 · fourth_quarter · Firm: FAEGRE BAKER DANIELS CONSULTING
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Client expense: — · Firm income: $15,000
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2016 · fourth_quarter · Firm: MYRIAD GENETIC LABORATORIES INC
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2017 Clinical Lab Fee Schedule rates; reconsideration process
Client expense: $260,000 · Firm income: —
Matched citations: HR 4302
Protecting Access to Medicare Act of 2014
2016 · third_quarter · Firm: MYRIAD GENETIC LABORATORIES INC
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests CY2016 Clinical Lab Fee Schedule amounts - Gapfill process
Client expense: $250,000 · Firm income: —
Matched citations: HR 4302
21st Century Cures Act
2016 · third_quarter · Firm: MYRIAD GENETIC LABORATORIES INC
FDA draft guidance to regulate laboratory developed tests, 21st Century Cures (HR 6), Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #)
Client expense: $250,000 · Firm income: —
Matched citations: HR 6
Source: Senate LDA